pharmaceutical investing Alexion Announces Successful Phase 3 PREVENT Study of Soliris (Eculizumab) in Patients with Neuromyelitis Optica Spectrum Disorder
pharmaceutical investing Alexion Submits Application for Approval of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria in the EU
pharmaceutical investing Positive Regulatory News from Two Pharmaceutical Companies Triggers Share Price Increases
LaFleur Minerals Continues to Expand Swanson Gold Deposit Mineralization Near Surface and Along Strike with 2.52 g/t Au over 14.35 Metres
Transition Metals Advances Saturday Night with Deep-Penetrating Geophysics, Reports 2026 Summer Exploration Results